La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Karolinska Development Gestione

Gestione criteri di controllo 3/4

Karolinska Development's Il CEO è Viktor Drvota, nominato in Jun2017, e ha un mandato di 7.17 anni. la retribuzione annua totale è SEK 4.73M, composta da 62.9% di stipendio e 37.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.078% delle azioni della società, per un valore di SEK 293.98K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.2 anni e 3.5 anni.

Informazioni chiave

Viktor Drvota

Amministratore delegato

SEK 4.7m

Compenso totale

Percentuale dello stipendio del CEO	62.9%
Mandato del CEO	7.2yrs
Proprietà del CEO	0.08%
Durata media del management	4.2yrs
Durata media del Consiglio di amministrazione	3.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

May 04

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Aug 19

Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year

Apr 27

We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings

Feb 08

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Viktor Drvota rispetto agli utili di Karolinska Development?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2024	n/a	n/a	SEK 34m
Dec 31 2023	SEK 5m	SEK 3m	SEK 5m
Sep 30 2023	n/a	n/a	SEK 17m
Jun 30 2023	n/a	n/a	-SEK 41m
Mar 31 2023	n/a	n/a	-SEK 87m
Dec 31 2022	SEK 6m	SEK 3m	-SEK 88m
Sep 30 2022	n/a	n/a	-SEK 118m
Jun 30 2022	n/a	n/a	-SEK 72m
Mar 31 2022	n/a	n/a	SEK 166m
Dec 31 2021	SEK 5m	SEK 3m	SEK 171m
Sep 30 2021	n/a	n/a	SEK 276m
Jun 30 2021	n/a	n/a	SEK 108m
Mar 31 2021	n/a	n/a	-SEK 106m
Dec 31 2020	SEK 5m	SEK 3m	-SEK 207m
Sep 30 2020	n/a	n/a	SEK 35m
Jun 30 2020	n/a	n/a	SEK 190m
Mar 31 2020	n/a	n/a	SEK 195m
Dec 31 2019	SEK 6m	SEK 3m	SEK 303m
Sep 30 2019	n/a	n/a	-SEK 11m
Jun 30 2019	n/a	n/a	SEK 8m
Mar 31 2019	n/a	n/a	SEK 32m
Dec 31 2018	SEK 5m	SEK 3m	SEK 31m
Sep 30 2018	n/a	n/a	SEK 48m
Jun 30 2018	n/a	n/a	SEK 238m
Mar 31 2018	n/a	n/a	SEK 185m
Dec 31 2017	SEK 5m	SEK 1m	SEK 180m

Compensazione vs Mercato: La retribuzione totale di Viktor ($USD 458.81K ) è superiore alla media delle aziende di dimensioni simili nel mercato Swedish ($USD 278.75K ).

Compensazione vs guadagni: La retribuzione di Viktor è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Viktor Drvota (59 yo)

7.2yrs

Mandato

SEK 4,733,000

Compensazione

Dr. Viktor Drvota, M.D., Ph D., has been an Independent Director of OssDsign AB since 2015. He serves as Chairman of the Board at Modus Therapeutics Holding Ab since 2016.He serves as the Chief Executive...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Viktor Drvota	Chief Executive Officer	7.2yrs	SEK 4.73m	0.078% SEK 288.5k
Hans Toll	Chief Financial Officer	1.8yrs	Nessun dato	0.013% SEK 48.1k
Per Aniansson	Investment Director	3.4yrs	Nessun dato	0.059% SEK 219.9k
Eva Montgomerie	Head of Accounting	10.8yrs	Nessun dato	0.012% SEK 45.5k
John Öhd	Chief Scientific Officer & Venture Partner	4.2yrs	Nessun dato	Nessun dato
Johan Dighed	Chief Legal Officer & Deputy CEO	4.3yrs	Nessun dato	0.15% SEK 549.9k
Yan Cheng	President of Asia	7.1yrs	Nessun dato	0.0093% SEK 34.4k
Tse Ping	Senior Strategic Advisor	no data	Nessun dato	Nessun dato
Linda Spahiu	Investment Manager	no data	Nessun dato	0.0037% SEK 13.8k
Mikaela Sörman	Investment Manager	no data	Nessun dato	0.0037% SEK 13.8k

4.2yrs

Durata media

54.5yo

Età media

Gestione esperta: Il team dirigenziale di KDEV è considerato esperto (durata media dell'incarico 4.2 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Hans Wigzell	Chairman	less than a year	SEK 500.00k	Nessun dato
Anna Lefevre Skjoldebrand	Independent Director	3.5yrs	SEK 200.00k	Nessun dato
Y. Y. Tse	Director	7.6yrs	Nessun dato	Nessun dato
Ben Toogood	Director	3.5yrs	SEK 178.00k	0.024% SEK 87.9k
Philip Duong	Director	2.6yrs	SEK 200.00k	Nessun dato

3.5yrs

Durata media

48yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di KDEV sono considerati esperti (durata media dell'incarico 3.5 anni).

Karolinska Development Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Chief Executive Officer recently bought kr81k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Recent updates

Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025

We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings

First quarter 2024 earnings released

Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

New major risk - Revenue and earnings growth

Chief Executive Officer recently bought kr81k worth of stock

Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)

Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024

Third quarter 2023 earnings released: EPS: kr0.044 (vs kr0.17 loss in 3Q 2022)

Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.

Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery

Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)

Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock

Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)

Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data

Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock

Third quarter 2022 earnings released

Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023

Karolinska Development AB (publ), Annual General Meeting, May 16, 2023

Price target decreased to kr5.40

Less than half of directors are independent

Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin

Karolinska Development AB Announces Chief Financial Officer Changes

Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria

Second quarter 2022 earnings released

Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047

Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Investor sentiment improved over the past week

First quarter 2022 earnings released

Price target increased to kr7.90

Less than half of directors are independent

Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study

Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.

Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)

Is Karolinska Development (STO:KDEV) Using Too Much Debt?

Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program

Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.

First quarter 2021 earnings released

Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

CFO & Deputy CEO Fredrik Jarrsten has left the company

Karolinska Development AB Announces CFO Changes

Karolinska Development Appoints Johan Dighed as Deputy CEO

New 90-day low: kr1.59

Karolinska Development AB (publ) Announces Management Appointments

Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)

New 90-day low: kr1.61

We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings

New 90-day low: kr1.80

Investor sentiment deteriorated over the past week

New 90-day low: kr2.17

New 90-day low: kr2.31

New 90-day low: kr2.60

New 90-day low: kr2.61